Genentech, Inc.

David Goldstein

Zachary Kevin Sweeney

Stephen Colin Price

Daniel P Sutherlin

Brian Salvatore Safina

Matthew C Lucas

Georgette M Castanedo

Pascal Pierre Alexandre Savy

Rama Kondru

Wylie Palmer

Bryan K Chan

Formula I (Ia and Ib) compounds wherein (i) Xis N and Xis S, (ii) Xis CRand Xis S, (iii) Xis N and Xis NR, or (iv) Xis CRand Xis O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use

Formula I (Ia and Ib) compounds wherein (i) Xis N and Xis S, (ii) Xis CRand Xis S, (iii) Xis N and Xis NR, or (iv) Xis CRand Xis O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Formula I (Ia and Ib) compounds wherein (i) Xis N and Xis S, (ii) Xis CRand Xis S, (iii) Xis N and Xis NR, (iv) Xis CRand Xis O, or (v) Xis CRand Xis NR, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use

Growing community of inventors

Nutley, NJ, United States of America

David Goldstein